TRC Names Jeff Butler Senior Vice President LOWELL,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TRC Names Jeff Butler Senior Vice President

LOWELL, MA--(Marketwired - Jul 21, 2014) - TRC Companies, Inc. ( NYSE : TRR ) announced today that Jeff Butler, PE has joined as Senior Vice President of Power & Utility Development. In this role, Butler will lead the strategic growth of the Company's engineering, environmental and infrastructure services within the power and utility market sectors, developing innovative strategies to maximize new business opportunities and supporting the delivery of creative solutions to client challenges.

"With more than 30 years of industry experience, Jeff's knowledge and relationships will create value for our Company and our clients," said TRC's Chairman and Chief Executive Officer Chris Vincze . "Jeff is an influential leader, and we look forward to his contributions to the success of our Power & Utility Development Initiative."

Prior to joining TRC, Butler was President and Chief Operating Officer for the Connecticut Light and Power Company where he was responsible for the development of the business strategies, overall operation, maintenance and construction of the electric distribution system as well as regulatory and legislative matters.

"For over 40 years, TRC has served the electric utility industry with engineering and environmental compliance support," said Butler. "I look forward to growing TRC's power and utility related business, building relationships with clients, and expanding TRC's service portfolio to meet the needs of the power and utility industries."

Previously, Butler spent more than 28 years at Pacific Gas and Electric Company retiring as Senior Vice President Energy Delivery. During his time at PG&E he held leadership positions covering all aspects of electric and gas transmission and distribution, including operations, maintenance, construction, engineering, as well as hydro generation.

Butler is a Registered Professional Engineer and holds a Bachelor of Science Degree in Electrical - Electronic Engineering from the California State University, Chico. He later completed the Executive Development Program at the University of Chicago.

About TRC A pioneer in groundbreaking scientific and engineering developments since the 1960s, TRC is a national engineering, consulting and construction management firm that provides integrated services to the energy , environmental and infrastructure markets. TRC serves a broad range of clients in government and industry, implementing complex projects from initial concept to delivery and operation. TRC delivers results that enable clients to achieve success in a complex and changing world. For more information and updates from the Company, visit TRC's website at www.TRCsolutions.com and follow TRC on Twitter and StockTwits at @TRC_Companies and on LinkedIn .

Forward-Looking Statements Certain statements in this press release may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by forward-looking words such as "may," "expects," "plans," "anticipates," "believes," "estimates," or other words of similar import. You should consider statements that contain these words carefully because they discuss TRC's future expectations, contain projections of the Company's future results of operations or of its financial condition, or state other "forward-looking" information. TRC believes that it is important to communicate its future expectations to its investors. However, there may be events in the future that the Company is not able to accurately predict or control and that may cause its actual results to differ materially from the expectations described in its forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, and actual results may differ materially from those discussed as a result of various factors, including, but not limited to, the uncertainty of TRC's operational and growth strategies; circumstances which could create large cash outflows, such as contract losses, litigation, uncollectible receivables and income tax assessments; regulatory uncertainty; the availability of funding for government projects; the level of demand for TRC's services; product acceptance; industry-wide competitive factors; the ability to continue to attract and retain highly skilled and qualified personnel; the availability and adequacy of insurance; and general political or economic conditions. Furthermore, market trends are subject to changes, which could adversely affect future results. See the risk factors and additional discussion in TRC's Annual Report on Form 10-K for the fiscal year ended June 30, 2013, Quarterly Reports on Form 10-Q, and other factors detailed from time to time in the Company's other filings with the Securities and Exchange Commission.

Company Contacts: Angela Cincotta (978) 656-3594 acincotta@trcsolutions.com Investor Contact: Sharon Merrill Associates (617) 542-5300 trr@investorrelations.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Elis Announces Share Buyback Operations Details and Impact

Updated Category News Views 257

Elis Announces Share Buyback Operations Recent Trading Disclosure by Elis In alignment with European regulations governing share buybacks, Elis has disclosed transactions for the purchase of its own shares. These operations occurred from September 15 to September 19, 2025, as part of an authorized buyback program approved by the General Shareholders' Meeting earlier in...

Continue Reading
One Stop Systems Set To Showcase Innovations at ROTH Event

Updated Category News Views 122

One Stop Systems Announces Participation in Major Conference One Stop Systems, Inc. (OSS), renowned for its cutting-edge solutions in rugged Enterprise Class computing, is gearing up to engage with investors at a prominent industry event. This year, OSS will be present at the 37th Annual ROTH Conference, scheduled for mid-March. The event will serve as a platform for the...

Continue Reading
Solid Biosciences to Engage at BioPharma Symposium Soon

Updated Category News Views 80

Solid Biosciences to Participate at BioPharma Symposium Solid Biosciences Inc. (NASDAQ: SLDB), a pioneering life sciences company, is excited to announce a significant upcoming event where they will showcase their advancements in the field of precision genetic medicine. The company's Chief Medical Officer, Dr. Gabriel Brooks, is scheduled to participate in a Genetic...

Continue Reading
JD Vance Confronted by Protesters While Out with Daughter

Updated Category News Views 378

Intense Encounter for Vice President JD Vance Recently, Vice President JD Vance found himself in a challenging situation when he was confronted by a group of pro-Ukraine protesters while spending time with his daughter. This encounter, which took place in Ohio, captured not only the essence of political tensions but also brought forth the complexities of personal moments...

Continue Reading
Exciting Addition to MyCardiologist as Dr. Koshy Joins Team

Updated Category News Views 325

New Addition to MyCardiologist Enhances Cardiovascular Care MyCardiologist, a leading name in advanced cardiovascular care, proudly announces the joining of Dr. Linda Koshy to their reputable medical team. Dr. Koshy is a skilled general and interventional cardiologist known for her exceptional ability to manage intricate coronary artery disease as well as endovascular...

Continue Reading